Klonopin (clonazepam) is from a class of medicines called benzodiazepines, which belong to the group called central nervous system (CNS) depressants. Clonazepam’s primary use is for seizures and panic attacks but it is sometimes used to treat tremor and occasionally used to manage pain or spasticity when other medicines don’t work.

Its mechanism of action is not fully understood, but it is believed that clonazepam has the capacity to enhance the activity of the major inhibitory neurotransmitter in the central nervous system, slowing it down.

Some of the side effects that clonazepam may cause are: drowsiness, problems with walking and coordination, dizziness, depression, fatigue and problems with memory.

Clonazepam has a black box warning (information that appears on a prescription drug’s label and is designed to call attention to serious or life-threatening risks) concerning use with same class medicines, which may result in profound sedation, breathing difficulties, depression, coma, and death.

Klonopin is also available as a generic medicine.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

 

MS Patients Find Cannabis Helpful for Easing Pain, Spasticity, Study Reports

About 85% of people with multiple sclerosis (MS) using cannabis find it to be helpful for pain, and 79% find it eases spasticity, a new study reports. The study, “Cannabis use in people with multiple sclerosis and spasticity: A cross-sectional analysis,” was published in the journal Multiple Sclerosis and Related Disorders. A previous review study that examined the […]

THC:CBD Oral Spray Sativex Provides Consistent Relief for Treatment-resistant MS Spasticity

Sativex (nabiximols), a THC:CBD oral spray, consistently relieves the pain and severity of treatment-resistant spasticity in multiple sclerosis (MS) patients, according to a recent study. An analysis of the Sativex as Add-on therapy Vs. further optimized first-line ANTispastics (SAVANT) study revealed that Sativex, used in conjunction with an anti-spasticity medication, provided strong and consistent relief from the symptoms and […]

I Am Beautifully Rare Despite SPMS

I have secondary progressive multiple sclerosis and I am rare. In honor of Rare Disease Day on Feb. 29, I honor myself. I honor you and anyone else with a rare disease. I have been asked if multiple sclerosis qualifies as a rare disease. It does if you have MS. I became rare on Nov. […]

Flowonix’s Prometra II Pump System Receives FDA Approval for Use with Intrathecal Baclofen

  The U.S. Food and Drug Administration (FDA) has granted approval to Flowonix Medical’s Prometra II Programmable Pump System for use with intrathecal baclofen for the treatment of spasticity across numerous conditions, including multiple sclerosis. Intrathecal baclofen — sold as Gablofen by Piramal, Lioresal by Saol Therapeutics, and also in generic formulations – is administered via an injection into […]

Sativex, Cannabis Extract for MS Spasticity, Now Available to Select Patients in England

The cannabis sativa plant extract Sativex is a cost-effective therapy for spasticity in multiple sclerosis (MS) and can be offered to patients in England needing it on at least a monthlong trial basis, the National Institute for Health and Care Excellence (NICE) said in issuing a final recommendation on the treatment. This decision reverses a previous draft guidance that […]

‘Soothie Cushion’ Designed to Regulate Body Temperature in Travelers With MS, Other Disabilities

Newly launched, the Soothie Cushion is designed to provide seating comfort and help regulate the body temperature of travelers with disabilities, including multiple sclerosis (MS) and myasthenia gravis, says its official retailer, Special Needs Group/Special Needs at Sea (SNG). The product is said to offer enduring comfort to wheelchair users through hot and cold therapy. What […]

#ECTRIMS2019 – Mollii Suit Can Ease Muscle Stiffness and Improve Movement, Reports State

Mollii, an electrostimulation suit, can help reduce muscle stiffness, or spasticity, and its associated pain, as well as improve muscle activation in people with multiple sclerosis (MS), cerebral palsy, stroke, and other neurological injuries, according to Inerventions, the Swedish company that developed and markets it. With a few hours of weekly treatment people report better control […]

MS News that Caught My Eye Last Week: Dark Rimmed Lesions, Sativex in the UK, NHS Care Toolkit for Neurological Diseases, Wahls Diet

Dark Rimmed Brain Lesions May Be Signal of Aggressive Disease, NIH Study Says Researchers in this study found that specific brain lesions, notable for their dark rims, may indicate that a patient’s multiple sclerosis is likely to progress quickly. They suggest that early detection of these lesions can help doctors to decide to begin aggressive […]

NICE and NHS England Oppose Sativex to Treat Spasticity in MS, Urge More Studies of Medical Cannabis

A draft guidance issued by the National Institute for Health and Care Excellence (NICE), a U.K. advisory board, and a review by England’s National Health Service (NHS) call for more research into medical cannabis for multiple sclerosis and other conditions. NICE also recommended against prescribing Sativex as a treatment for spasticity (muscle stiffness) in people with  MS for reasons related […]